Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine ofLeishmania donovani
The nucleoside hydrolase (NH36) ofLeishmania (L.) donovaniis a vital enzyme which releases purines or pyrimidines of foreign DNA to be used in the synthesis of parasite DNA. As a bivalent DNA vaccine, the VR1012-NH36 was immunoprotective against visceral and cutaneous murine leishmaniasis. In this w...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2006-05, Vol.24 (22), p.4863 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 22 |
| container_start_page | 4863 |
| container_title | Vaccine |
| container_volume | 24 |
| creator | Gamboa-León, R Paraguai de Souza, E Borja-Cabrera, GP Santos, FN Myashiro, LM Pinheiro, RO Dumonteil, E Palatnik-de-Sousa, CB |
| description | The nucleoside hydrolase (NH36) ofLeishmania (L.) donovaniis a vital enzyme which releases purines or pyrimidines of foreign DNA to be used in the synthesis of parasite DNA. As a bivalent DNA vaccine, the VR1012-NH36 was immunoprotective against visceral and cutaneous murine leishmaniasis. In this work we tested the immunotherapy againstLeishmania (L.) chagasiinfection, using two doses of 100 or 20μg VR1012-NH36 vaccine (i.m. route), and, as a possible immunomodulator, aqueous garlic extract (8mg/kg/day by the i.p. route), which was effective in immunotherapy of cutaneous murine leishmaniasis. Liver parasitic load was significantly reduced following treatment with 100μg (91%) and 20μg (77%) of the DNA vaccine, and by 20μg DNA vaccine and garlic extract (76%) (p=0.023). Survival was 33% for saline controls, 100% for the 100μg vaccine, and 83 and 67% for the 20μg vaccine with and without garlic extract addition, respectively. Garlic treatment alone did not reduce parasite load (p>0.05), but increased survival (100%). The NH36-DNA vaccine was highly effective as a new tool for the therapy and control of visceral leishmaniasis, while the mild protective effect of garlic might be related to an unspecific enhancement of IFN-γ secretion. |
| doi_str_mv | 10.1016/j.vaccine.2006.03.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1559012347</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3420537181</sourcerecordid><originalsourceid>FETCH-proquest_journals_15590123473</originalsourceid><addsrcrecordid>eNqNjs1qwzAQhEVIoe7PIxQWera6a9lOcixpQgulpx56C8JWahlZSry2Q96-OoSec5ph5hsYIZ4IJSGVL62cdFVZb2SGWEpUErGYiYSWC5VmBS3nIsGszNOc8OdW3DG3GAlFq0S4j64bfRga0-vDGfSvtp4HmCxXMXHgjOWm095qtgwnOzQQWfBj5UxgWxtoznUfnGaTvn29wuUJhP3n_xLq4MMU3YO42WvH5vGi9-J5u_lev6eHPhxHw8OuDWPvY7WjolghZSpfqOuoPwKRU00</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1559012347</pqid></control><display><type>article</type><title>Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine ofLeishmania donovani</title><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Gamboa-León, R ; Paraguai de Souza, E ; Borja-Cabrera, GP ; Santos, FN ; Myashiro, LM ; Pinheiro, RO ; Dumonteil, E ; Palatnik-de-Sousa, CB</creator><creatorcontrib>Gamboa-León, R ; Paraguai de Souza, E ; Borja-Cabrera, GP ; Santos, FN ; Myashiro, LM ; Pinheiro, RO ; Dumonteil, E ; Palatnik-de-Sousa, CB</creatorcontrib><description>The nucleoside hydrolase (NH36) ofLeishmania (L.) donovaniis a vital enzyme which releases purines or pyrimidines of foreign DNA to be used in the synthesis of parasite DNA. As a bivalent DNA vaccine, the VR1012-NH36 was immunoprotective against visceral and cutaneous murine leishmaniasis. In this work we tested the immunotherapy againstLeishmania (L.) chagasiinfection, using two doses of 100 or 20μg VR1012-NH36 vaccine (i.m. route), and, as a possible immunomodulator, aqueous garlic extract (8mg/kg/day by the i.p. route), which was effective in immunotherapy of cutaneous murine leishmaniasis. Liver parasitic load was significantly reduced following treatment with 100μg (91%) and 20μg (77%) of the DNA vaccine, and by 20μg DNA vaccine and garlic extract (76%) (p=0.023). Survival was 33% for saline controls, 100% for the 100μg vaccine, and 83 and 67% for the 20μg vaccine with and without garlic extract addition, respectively. Garlic treatment alone did not reduce parasite load (p>0.05), but increased survival (100%). The NH36-DNA vaccine was highly effective as a new tool for the therapy and control of visceral leishmaniasis, while the mild protective effect of garlic might be related to an unspecific enhancement of IFN-γ secretion.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2006.03.005</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><subject>Deoxyribonucleic acid ; DNA ; Dogs ; Immunotherapy ; Parasites ; Parasitic diseases ; Rodents ; Vaccines ; Vector-borne diseases</subject><ispartof>Vaccine, 2006-05, Vol.24 (22), p.4863</ispartof><rights>Copyright Elsevier Limited May 29, 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1559012347?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,64383,64387,72239</link.rule.ids></links><search><creatorcontrib>Gamboa-León, R</creatorcontrib><creatorcontrib>Paraguai de Souza, E</creatorcontrib><creatorcontrib>Borja-Cabrera, GP</creatorcontrib><creatorcontrib>Santos, FN</creatorcontrib><creatorcontrib>Myashiro, LM</creatorcontrib><creatorcontrib>Pinheiro, RO</creatorcontrib><creatorcontrib>Dumonteil, E</creatorcontrib><creatorcontrib>Palatnik-de-Sousa, CB</creatorcontrib><title>Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine ofLeishmania donovani</title><title>Vaccine</title><description>The nucleoside hydrolase (NH36) ofLeishmania (L.) donovaniis a vital enzyme which releases purines or pyrimidines of foreign DNA to be used in the synthesis of parasite DNA. As a bivalent DNA vaccine, the VR1012-NH36 was immunoprotective against visceral and cutaneous murine leishmaniasis. In this work we tested the immunotherapy againstLeishmania (L.) chagasiinfection, using two doses of 100 or 20μg VR1012-NH36 vaccine (i.m. route), and, as a possible immunomodulator, aqueous garlic extract (8mg/kg/day by the i.p. route), which was effective in immunotherapy of cutaneous murine leishmaniasis. Liver parasitic load was significantly reduced following treatment with 100μg (91%) and 20μg (77%) of the DNA vaccine, and by 20μg DNA vaccine and garlic extract (76%) (p=0.023). Survival was 33% for saline controls, 100% for the 100μg vaccine, and 83 and 67% for the 20μg vaccine with and without garlic extract addition, respectively. Garlic treatment alone did not reduce parasite load (p>0.05), but increased survival (100%). The NH36-DNA vaccine was highly effective as a new tool for the therapy and control of visceral leishmaniasis, while the mild protective effect of garlic might be related to an unspecific enhancement of IFN-γ secretion.</description><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Dogs</subject><subject>Immunotherapy</subject><subject>Parasites</subject><subject>Parasitic diseases</subject><subject>Rodents</subject><subject>Vaccines</subject><subject>Vector-borne diseases</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNjs1qwzAQhEVIoe7PIxQWera6a9lOcixpQgulpx56C8JWahlZSry2Q96-OoSec5ph5hsYIZ4IJSGVL62cdFVZb2SGWEpUErGYiYSWC5VmBS3nIsGszNOc8OdW3DG3GAlFq0S4j64bfRga0-vDGfSvtp4HmCxXMXHgjOWm095qtgwnOzQQWfBj5UxgWxtoznUfnGaTvn29wuUJhP3n_xLq4MMU3YO42WvH5vGi9-J5u_lev6eHPhxHw8OuDWPvY7WjolghZSpfqOuoPwKRU00</recordid><startdate>20060529</startdate><enddate>20060529</enddate><creator>Gamboa-León, R</creator><creator>Paraguai de Souza, E</creator><creator>Borja-Cabrera, GP</creator><creator>Santos, FN</creator><creator>Myashiro, LM</creator><creator>Pinheiro, RO</creator><creator>Dumonteil, E</creator><creator>Palatnik-de-Sousa, CB</creator><general>Elsevier Limited</general><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20060529</creationdate><title>Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine ofLeishmania donovani</title><author>Gamboa-León, R ; Paraguai de Souza, E ; Borja-Cabrera, GP ; Santos, FN ; Myashiro, LM ; Pinheiro, RO ; Dumonteil, E ; Palatnik-de-Sousa, CB</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_15590123473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Dogs</topic><topic>Immunotherapy</topic><topic>Parasites</topic><topic>Parasitic diseases</topic><topic>Rodents</topic><topic>Vaccines</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gamboa-León, R</creatorcontrib><creatorcontrib>Paraguai de Souza, E</creatorcontrib><creatorcontrib>Borja-Cabrera, GP</creatorcontrib><creatorcontrib>Santos, FN</creatorcontrib><creatorcontrib>Myashiro, LM</creatorcontrib><creatorcontrib>Pinheiro, RO</creatorcontrib><creatorcontrib>Dumonteil, E</creatorcontrib><creatorcontrib>Palatnik-de-Sousa, CB</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gamboa-León, R</au><au>Paraguai de Souza, E</au><au>Borja-Cabrera, GP</au><au>Santos, FN</au><au>Myashiro, LM</au><au>Pinheiro, RO</au><au>Dumonteil, E</au><au>Palatnik-de-Sousa, CB</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine ofLeishmania donovani</atitle><jtitle>Vaccine</jtitle><date>2006-05-29</date><risdate>2006</risdate><volume>24</volume><issue>22</issue><spage>4863</spage><pages>4863-</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>The nucleoside hydrolase (NH36) ofLeishmania (L.) donovaniis a vital enzyme which releases purines or pyrimidines of foreign DNA to be used in the synthesis of parasite DNA. As a bivalent DNA vaccine, the VR1012-NH36 was immunoprotective against visceral and cutaneous murine leishmaniasis. In this work we tested the immunotherapy againstLeishmania (L.) chagasiinfection, using two doses of 100 or 20μg VR1012-NH36 vaccine (i.m. route), and, as a possible immunomodulator, aqueous garlic extract (8mg/kg/day by the i.p. route), which was effective in immunotherapy of cutaneous murine leishmaniasis. Liver parasitic load was significantly reduced following treatment with 100μg (91%) and 20μg (77%) of the DNA vaccine, and by 20μg DNA vaccine and garlic extract (76%) (p=0.023). Survival was 33% for saline controls, 100% for the 100μg vaccine, and 83 and 67% for the 20μg vaccine with and without garlic extract addition, respectively. Garlic treatment alone did not reduce parasite load (p>0.05), but increased survival (100%). The NH36-DNA vaccine was highly effective as a new tool for the therapy and control of visceral leishmaniasis, while the mild protective effect of garlic might be related to an unspecific enhancement of IFN-γ secretion.</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1016/j.vaccine.2006.03.005</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2006-05, Vol.24 (22), p.4863 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_journals_1559012347 |
| source | ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Deoxyribonucleic acid DNA Dogs Immunotherapy Parasites Parasitic diseases Rodents Vaccines Vector-borne diseases |
| title | Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine ofLeishmania donovani |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T05%3A18%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunotherapy%20against%20visceral%20leishmaniasis%20with%20the%20nucleoside%20hydrolase-DNA%20vaccine%20ofLeishmania%20donovani&rft.jtitle=Vaccine&rft.au=Gamboa-Le%C3%B3n,%20R&rft.date=2006-05-29&rft.volume=24&rft.issue=22&rft.spage=4863&rft.pages=4863-&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2006.03.005&rft_dat=%3Cproquest%3E3420537181%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1559012347&rft_id=info:pmid/&rfr_iscdi=true |